Cero Analysis: $1M Raised
What is Cero?
Cero AI offers an automated communication platform for healthcare, facilitating task coordination between hospitals and patients via WhatsApp for appointment management.
Founded
2016
Revenue
$7.3M
Investors
- Y Combinator
- Crossbeam Venture Partners
Product Features & Capabilities
- Tumor cell clearance therapies, CER T-cell platform, engineered T cell therapeutics, targeting hematologic malignancies, targeting solid tumors, high yields of drug product, favorable memory and immunophenotypic profiles.
How much Cero raised
Series A - $1.25M
Sep 26, 2024Lead Investor: Not specified
Business Model
Focus on clinical trials and funding through public offerings and private placements.
Competitors Overview
Cero Therapeutics operates in the biotechnology sector, focusing on innovative tumor cell clearance through its CER technology platform. Its main competitors include:
- TCR CURE Biopharma: This company develops cancer immunotherapies and is a private entity founded in 2017. It is headquartered
Market Focus
Cero Therapeutics primarily focuses on the biotechnology industry, specifically in the area of tumor cell clearance through their innovative CER technology platform.
See something that needs updating? Suggest edits to this profile.